EULAR 2022 | The BE MOBILE 1 and 2 trials of bimekizumab in axSpA | rheumatology.medicinematters.com

Register Login

Medicine Matters Rheumatology

JAVASCRIPT NEEDED

Please enable JavaScript on your browser, so that you can use all features of this website.

window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'event': 'track', 'eventCategory': 'flash_warning', 'eventAction': 'Javascript needed', 'eventLabel': 'Please enable JavaScript on your browser, so that you can use all features of this website.' });

14-06-2022 | EULAR 2022 | Conference coverage | Video

The BE MOBILE 1 and 2 trials of bimekizumab in axSpA

Désirée van der Heijde outlines the findings of two phase 3 trials demonstrating that bimekizumab may be beneficial for patients with nonradiographic axial spondyloarthritis or ankylosing spondylitis (2:54).

Related content

25-05-2022 | Bimekizumab | Feature | Article

A quick guide to the phase 3 trials of bimekizumab in spondyloarthritis

14-06-2019 | Axial spondyloarthritis | EULAR 2019 | News

BE AGILE: Bimekizumab shows promise for ankylosing spondylitis

12-11-2019 | Ankylosing spondylitis | ACR/ARP 2019 | News

Bimekizumab benefits for ankylosing spondylitis extend beyond 12 weeks

04-06-2022 | EULAR 2022 | Conference coverage | News

Bimekizumab beneficial for psoriatic arthritis in phase 3 trials

Version: 0.2002.0